#NTHi

#NTHI NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

NeOnc Technologies Reports Updated Clinical Results NeOnc Technologies (NASDAQ:NTHI) reported updated Phase 1/2a and compassionate-use data (cohort n=24) for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma on Nov 12, 2025. Key outcomes: a 21% radiographic response rate (5/24) confirmed by contrast-enhanced and perfusion MRI, 44% PFS‑6 (6‑month progression‑free survival), and 33% alive ≥18 months (8/24). No significant toxicity was reported with prolonged intranasal dosing. The company frames these results as exceeding historical salvage-therapy benchmarks (

#NTHI NeOnc Technologies Reports Updated Clinical Results

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Leading Indicators, Tuesday November 11, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Tue Nov 11th - #STAA #ORMP #ADSE #BCIC #CECO #DSGN #EWTX #GANX #HCAI #INNV #PUBM #NTHI #YEXT #VAN #SFL #NVRI #KOP #FIGS #DV #BAK - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals NeOnc Technologies (NASDAQ:NTHI) announced that, after receiving required UAE tax and regulatory approvals, a previously signed definitive agreement with Abu Dhabi-based Quazar Investment for a $50 million strategic equity partnership is mandated to close no later than October 23, 2025. The deal centers on Abu Dhabi operating subsidiary NuroCure under NuroMENA Holdings, which was incorporated in the Abu Dhabi Global Market on August 6, 2025, satisfying closing contingencies. The partnership allocates $15 million specifically to Phase 2B clinical trials and UAE/MENA infrastructure development and aims to accelerate NeOnc’s pipeline, including NEO100 (multiple trials) and NEO212 programs, plus a pediatric NEO100-03 Phase 1 trial, in collaboration with Cleveland Clinic UAE.

#NTHI NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

Market Wire News

@marketwirenews.com

6 months ago

News; ( NASDAQ: #NTHI ) NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 - A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board NeOnc Technologies (NASDAQ:NTHI) has completed the acquisition of a strategic intellectual property portfolio focused on AI, 3D bioprinting, and quantum modeling technologies for $3.5 million ($500,000 cash and $3 million in stock at $25/share). The acquired technology, including U.S. Patent No. 11,788,057 B2, enables the creation of sophisticated patient-derived 3D brain tumor models.The acquisition enhances NeOnc's drug discovery capabilities by combining AI and quantum modeling algorithms with realistic biological environments for more efficient therapeutic candidate screening. Alongside this development, the company appointed Dr. Ishwar K. Puri, Senior Vice President of Research and Innovation at USC and a globally recognized scholar, to its Board of Directors.

#NTHI NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update NeOnc Technologies (NASDAQ: NTHI), a clinical-stage biotech company focused on CNS cancer therapies, reported Q2 2025 results and significant operational developments. The company secured a $50 million strategic partnership with Quazar Investment and received a $2.5 million NIH grant. Key financial metrics show increased expenses with G&A at $984K (up from $290K) and R&D at $677K (up from $394K), resulting in a net loss of $5.68M.Clinical progress includes advancing multiple trials: NEO100-01 for malignant gliomas (Phase 2a enrollment expected by September 2025), NEO212 for brain cancer (final Phase I cohort completion in 2025), and NEO100-3 for pediatric indications. The company also acquired an AI and quantum modeling IP portfolio and joined the Russell Microcap® Index.

#NTHI NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation NeOnc Technologies (NASDAQ: NTHI), a multi-Phase 2 clinical-stage biotech company, has completed all contingencies for a $50 million strategic partnership with Quazar Investment following the incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM).The partnership involves Quazar Investment taking majority control of NuroMENA Holdings, which will serve as NeOnc's UAE-based subsidiary overseeing regional clinical operations in the Middle East and North Africa. The collaboration aims to accelerate the development of NeOnc's CNS therapeutic pipeline, including the NEO212 and NEO100 clinical programs for brain cancer treatment.Quazar Investment, managing over $3.3 billion in assets, will provide strategic support to expand NeOnc's CNS platform across the MENA region, with joint governance oversight between both companies.

#NTHI NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia NeOnc Technologies (NASDAQ: NTHI) has secured $2.5 million in NIH STTR grants to advance its proprietary compound NEO212. The funding includes a $400,000 Phase 1 grant for acute myelogenous leukemia (AML) studies and a $2.1 million Phase 2 grant for newly diagnosed gliomas research.The company is currently completing Phase 1 clinical trials for NEO212, with these non-dilutive funds supporting its expansion into new indications. The grants are structured as collaborative developments between NeOnc (40% funding) and USC-based research collaborators (60% funding), led by Dr. Thomas Chen as Principal Investigator.

#NTHI NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

NeOnc Unveils $50M Partnership and AI Brain Cancer Breakthrough Strategy on Yahoo Finance Interview From Russell Index inclusion to $50M partnership, NeOnc's CEO shares expansion plans for AI-enhanced brain cancer treatment. Learn about the USC collaboration. Get insights.

#NTHI NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

$50M Deal: NeOnc Technologies Partners with Quazar to Revolutionize Brain Cancer Treatment in MENA Region Major $50M partnership fuels Phase 2B brain cancer trials and MENA expansion. Premium $25/share investment backs clinical advancement. Learn expansion details.

#NTHI NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment NeOnc Technologies (NTHI) has executed a crucial Sub-License Agreement with its Abu Dhabi subsidiary NuroCure, marking significant progress toward closing a $50 million strategic partnership with Quazar Investment. The agreement, covering NEO100 and NEO212 in the UAE and MENA region, represents the second of five required conditions for the transaction.The partnership, priced at $25 per share, allocates 70% for NeOnc common stock acquisition and 30% for MENA region clinical trials and infrastructure. The company must complete three remaining conditions within 120 days, including forming NuroMENA and NuroCure in Abu Dhabi, finalizing offering documents, and approving a two-year business plan.NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials with FDA Fast-Track status, targeting brain and central nervous system cancers.

#NTHI NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment NeOnc Technologies (NASDAQ: NTHI) has secured board approval for a strategic $50 million partnership with Quazar Investment. The board unanimously approved the company's participation in the equity investment and MENA region expansion on June 30, 2025, marking the first of five required milestones.The proposed structure includes a $25 per share pricing, with 70% of proceeds allocated to NeOnc common stock acquisition and 30% dedicated to clinical trials and infrastructure development in the UAE and MENA region. The company must complete remaining conditions within 120 days, including establishing NuroMENA and NuroCure in Abu Dhabi, executing licensing agreements for NEO100 and NEO212, and finalizing offering documents and business plans.

#NTHI NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

NeOnc Technologies Holdings, Inc. Joins Russell Microcap® Index NeOnc Technologies Holdings (NASDAQ: NTHI), a clinical-stage biopharmaceutical company developing CNS cancer treatments, has been added to the Russell Microcap® Index following its 2025 annual reconstitution. This inclusion positions NTHI among select companies with market caps between $30 million and $3 billion, representing less than 3% of the U.S. equity market.The company is currently advancing two Phase II clinical trials with its proprietary NEO100™ and NEO212™ therapeutics, both operating under FDA Fast-Track and IND status. NeOnc's drug development platform focuses on overcoming blood-brain barrier challenges, with patent protections extending to 2038. The company is also pursuing strategic expansion in the MENA region through a proposed partnership with Quazar in the GCC.

#NTHI NeOnc Technologies Holdings, Inc. Joins Russell Microcap® Index

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform NeOnc Technologies (NASDAQ: NTHI) has signed a $50 million non-binding term sheet with Quazar Investment to establish NuroMENA Holdings Ltd and its subsidiary NuroCure in the UAE. The strategic partnership aims to expand NeOnc's clinical trials for brain cancer treatments into the GCC & MENA regions.The deal includes a $50 million equity investment at $25 per share, with 70% allocated for NTHI common stock purchase and 30% for regional clinical trials and infrastructure. The partnership will leverage Cleveland Clinic Abu Dhabi's FDA-protocol trial facilities for NeOnc's drug candidates NEO100 and NEO212, targeting aggressive brain cancers DIPG and GBM.The transaction, expected to close by July 10, 2025, is subject to several conditions including board approval (completed June 30, 2025), legal formation of entities, and execution of sub-license agreements within 120 days.

#NTHI NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Thu May 8th - #DHX #EBS #CRVS #BMBL #FSLY #GFR #ACTG #MAGN #VCSA #QBTS #ZVIA #DAVE #ECPG #GRPN #ZKIN #SEZL #HDSN #JRSH #MRTN #NTHI #OM #RDVT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

NeOnc's Massive Patent Portfolio Locks Down Cancer Drug Market Through 2039 Biotech firm strengthens market position with 126 issued and 50 pending patents across US, EU, and Asia. Key cancer therapies protected until 2039. See full coverage details.

#NTHI NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Groundbreaking Brain Cancer Treatment Reaches Final Enrollment Stage in Critical Trial First-in-class intranasal therapy for malignant gliomas shows promise with FDA Fast Track status. Final trial patients being enrolled. Full data expected 2026.

#NTHI NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President NeOnc Technologies Holdings (NASDAQ: NTHI) has announced the appointment of Executive Chairman Amir Heshmatpour as the company's new President, while maintaining his role as Executive Chairman. This strategic move aims to accelerate the company's clinical initiatives, particularly focusing on central nervous system (CNS) cancers and disorders.Heshmatpour brings over 25 years of executive experience, notably founding AFH Holdings & Advisory where he led IPO transactions worth over $1.5 billion and M&A deals exceeding $5 billion. His previous success includes founding Metrophone Telecommunications, which under his leadership completed 17 acquisitions and achieved annual revenues over $100 million.In his expanded role, Heshmatpour will oversee daily operations while enabling CEO Dr. Thomas Chen to focus on advancing clinical trials, particularly patient enrollment for lead drug candidates NEO212 (TMZ bio-conjugate) and NEO100.

#NTHI NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Breakthrough Brain Cancer Treatment NEO212 Advances: Phase I Trial Hits Critical Milestone Revolutionary brain cancer therapy NEO212 shows promise in Phase I trial, combining TMZ with POH to overcome current treatment limitations. Full analysis inside.

#NTHI NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Game-Changing FDA Status: NEO100 Targets Rare Pediatric Brain Cancer with PRV Opportunity NEO100 earns special FDA designation for treating aggressive childhood brain tumors. Priority Review Voucher eligibility adds significant market potential. Full analysis inside.

#NTHI NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Major Breakthrough: NeOnc Accelerates Brain Cancer Research with 30-Site Global Expansion NeOnc partners with CBCC to add 30 FDA-compliant sites in India, fast-tracking Phase 2a glioblastoma trial enrollment. See expansion impact analysis.

#NTHI NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Major Biotech Direct Listing: NeOnc Tech Gets Green Light for Nasdaq Global Market Clinical-stage biotech NeOnc Technologies secures SEC approval for direct listing on Nasdaq Global Market. Trading starts March 2025. See investment details.

#NTHI NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market

www.stocktitan.net/news/NTHI/ne-onc-technol...

0 0 0 0

Infectious Diseases Fellowship at Indiana University

@iuidfellowship.bsky.social

1 year ago

burden of #NTHi infection extends into neonatal period
high incidence of invasive disease in 1st 28 days of life, esp in extremely premature neonate; incidence of invasive NTHi infection is 365-fold higher for neonates at <28wk gestation than for term neonates (>36wk gestation)

0 0 1 0

Infectious Diseases Fellowship at Indiana University

@iuidfellowship.bsky.social

1 year ago

Pregnancy is associated with a 17-fold increase in the incidence of invasive #Haemophilus #influenzae infection, largely caused by infection with #nontypeable H. influenzae #NTHi #chorioamnionitis or #intraamniotic infection (IAI) #IDsky

3 0 1 0

Posts tagged #NTHi